Browsing Tag
S&P Global Ratings
8 posts
Brookfield Renewable’s C$750m green-bond deal locks in two maturities as development pipeline tops 83GW
Brookfield Renewable has agreed to issue C$750 million of green bonds across 2031 and 2036 maturities, adding capital flexibility as its advanced-stage development pipeline approaches 84 GW.
August 21, 2026
Agibank reaches AA level across three Brazilian rating scales as loan book hits R$37.1bn
S&P Global Ratings has upgraded Agibank’s Brazilian national-scale rating to brAA with a stable outlook, completing a series of 2026 upgrades across three agencies. The move arrives as the bank rapidly expands lending and diversifies its funding base.
August 21, 2026
Georgia Capital clears final US$50m bond as debt-free holding company starts GEL 1bn capital programme
Georgia Capital is eliminating its final US$50 million holding-company bond while launching a GEL 1 billion programme spanning buybacks, dividends and new investment.
August 19, 2026
Munich Re (ETR: MUV2) trades 23% below 52-week high as reinsurance pricing softens into hurricane season
Munich Re beat Q1 by 57% and reaffirmed €6.3bn guidance. The stock is down 23%. The real question is whether softening renewal prices break the Ambition 2030 thesis.
May 17, 2026
Infratil (ASX: IFT) shares jump 11.7% on CDC’s record 555MW data centre deal
Hyperscalers are running out of US power. CDC just signed Australia's biggest ever data centre contract. Infratil holders now own the build.
May 6, 2026
Hut 8 (NASDAQ: HUT) stock faces AI infrastructure test as $3.25bn notes plan funds River Bend data center
Hut 8 wants AI infrastructure scale without equity dilution. Its $3.25B debt plan now tests whether River Bend can deliver.
April 27, 2026
Inside Galderma’s €500m bond deal and what it reveals about the dermatology market’s financial momentum
Galderma raises €500M via a five-year eurobond to refinance IPO debt and strengthen its balance sheet. Discover what this means for GALD investors.
March 11, 2026
Thermo Fisher raises $2.5bn in bonds—But what’s the bigger play behind the debt move?
Thermo Fisher Scientific priced $2.5B in senior notes to fuel acquisitions, refinancing, and growth. See how the deal shapes TMO’s 2026 outlook.
October 1, 2025